{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:43:26Z","timestamp":1789055006525,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1596,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1111\/j.1365-2710.2011.01249.x","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T06:56:10Z","timestamp":1303196170000},"page":"53-57","source":"Crossref","is-referenced-by-count":17,"title":["Content variability of active drug substance in compounded oral 3,4-diaminopyridine products"],"prefix":"10.1155","volume":"37","author":[{"given":"D. M.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,19]]},"reference":[{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB1|cit1","unstructured":"Orphanet: Lambert-Eaton Myasthnic Syndrome 2010 http:\/\/www.orpha.net"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/01.WNL.0000130254.27019.14","article-title":"The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands","volume":"63","author":"Wirtz","year":"2004","journal-title":"Neurology"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","article-title":"The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz","year":"2003","journal-title":"Journal of Neurology"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0022-3565(25)22023-7","article-title":"Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction","volume":"227","author":"Thomsen","year":"1983","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0006-8993(84)90875-8","article-title":"Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats","volume":"304","author":"Lemeignan","year":"1984","journal-title":"Brain Research"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/jnnp.47.9.1052","article-title":"Oral 3,4-diaminopyridine in the treatment of the Lambert-Eaton myasthenic syndrome (LEMS). Proceedings of the meeting of the Association of British Neurologists held jointly with the Polish Neurological Society in London, April 1984","volume":"47","author":"Murray","year":"1984","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1749-6632.1993.tb22949.x","article-title":"3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis","volume":"681","author":"Sanders","year":"1993","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":"A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":"3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle and Nerve"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1185\/03007991003745209","article-title":"Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment","volume":"26","author":"Quartel","year":"2010","journal-title":"Current Medical Research and Opinion"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1468-1331.2006.01266.x","article-title":"Management of paraneoplastic neurological syndromes: report of an EFNS Task Force","volume":"13","author":"Vedeler","year":"2006","journal-title":"European Journal of Neurology"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","article-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders","volume":"13","author":"Skeie","year":"2006","journal-title":"European Journal of Neurology"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpba.2006.06.007","article-title":"Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products","volume":"43","author":"Raust","year":"2007","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB16|cit16","unstructured":"The Council of the European Communities 1975 Council Directive 75\/319\/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products http:\/\/www.echamp.eu\/fileadmin\/user_upload\/Regulation\/Directive_75-319-EEC__-__Consolidated_Version.pdf"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1365\/s10337-006-0821-y","article-title":"HPLC method for determination of 3,4-diaminopyridine in the presence of related substances and degradation products formed under stress conditions","volume":"63","author":"Do","year":"2006","journal-title":"Chromatographia"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB18|cit18","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Limited FDA survey of compounded drug products http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/PharmacyCompounding\/ucm155725.htm"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/01.wnl.0000339380.23073.58","article-title":"4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis","volume":"71","author":"Burton","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB20|cit20","article-title":"Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error","author":"Schwam","journal-title":"The Journal of Emergency Medicine"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB21|cit21","unstructured":"Commission of the European Communities Commission decision of 18\/12\/2002 relating to the designation of medicinal product \u201c3,4-diaminopyridine phosphate\u201d as an orphan medicinal product"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB22|cit22","unstructured":"Committee for Medicinal Products for Human Use Committee for medicinal products for human use summary of positive opinion for ZENAS"},{"key":"10.1111\/j.1365-2710.2011.01249.x-BIB23|cit23","unstructured":"Firdapse Summary of Product Characteristics 2010 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001032\/WC500069915.pdf"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2011.01249.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2011.01249.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:19:53Z","timestamp":1741148393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2011.01249.x"}},"subtitle":["Content variability in compounded oral 3,4-diaminopyridine products"],"short-title":[],"issued":{"date-parts":[[2011,4,19]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2011.01249.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,19]]}}}